Cargando…

Supramolecular lipid nanoparticles as delivery carriers for non-invasive cancer theranostics

Nanotheranostics is an emerging frontier of personalized medicine research particularly for cancer, which is the second leading cause of death. Supramolecular aspects in theranostics are quite allured to achieve more regulation and controlled features. Supramolecular nanotheranostics architecture is...

Descripción completa

Detalles Bibliográficos
Autores principales: Bukhari, Syeda Zunaira, Zeth, Kornelius, Iftikhar, Maryam, Rehman, Mubashar, Usman Munir, Muhammad, Khan, Waheed S., Ihsan, Ayesha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8663983/
https://www.ncbi.nlm.nih.gov/pubmed/34909685
http://dx.doi.org/10.1016/j.crphar.2021.100067
_version_ 1784613759679987712
author Bukhari, Syeda Zunaira
Zeth, Kornelius
Iftikhar, Maryam
Rehman, Mubashar
Usman Munir, Muhammad
Khan, Waheed S.
Ihsan, Ayesha
author_facet Bukhari, Syeda Zunaira
Zeth, Kornelius
Iftikhar, Maryam
Rehman, Mubashar
Usman Munir, Muhammad
Khan, Waheed S.
Ihsan, Ayesha
author_sort Bukhari, Syeda Zunaira
collection PubMed
description Nanotheranostics is an emerging frontier of personalized medicine research particularly for cancer, which is the second leading cause of death. Supramolecular aspects in theranostics are quite allured to achieve more regulation and controlled features. Supramolecular nanotheranostics architecture is focused on engineering of modular supramolecular assemblies benefitting from their mutable and stimuli-responsive properties which confer an ultimate potential for the fabrication of unified innovative nanomedicines with controlled features. Amalgamation of supramolecular approaches to nano-based features further equip the potential of designing novel approaches to overcome limitations seen by the conventional theranostic strategies, for curing even the lethal diseases and endowing personalized therapeutics with optimistic prognosis, endorsing their clinical translation. Among many potential nanocarriers for theranostics, lipid nanoparticles (LNPs) have shown various promising advances in theranostics and their formulation can be tailored for several applications. Despite the great advancement in cancer nanotheranostics, there are still many challenges that need to be highlighted to fill the literature gap. For this purpose, herein, we have presented a systematic overview on the subject and proposed LNPs as the potential material to manage cancer via non-invasive approaches by highlighting the use of supramolecular approaches to make them robust for cancer theranostics. We have concluded the review by entailing the future perspectives of lipid nanotheranostics towards clinical translation.
format Online
Article
Text
id pubmed-8663983
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-86639832021-12-13 Supramolecular lipid nanoparticles as delivery carriers for non-invasive cancer theranostics Bukhari, Syeda Zunaira Zeth, Kornelius Iftikhar, Maryam Rehman, Mubashar Usman Munir, Muhammad Khan, Waheed S. Ihsan, Ayesha Curr Res Pharmacol Drug Discov Review Article Nanotheranostics is an emerging frontier of personalized medicine research particularly for cancer, which is the second leading cause of death. Supramolecular aspects in theranostics are quite allured to achieve more regulation and controlled features. Supramolecular nanotheranostics architecture is focused on engineering of modular supramolecular assemblies benefitting from their mutable and stimuli-responsive properties which confer an ultimate potential for the fabrication of unified innovative nanomedicines with controlled features. Amalgamation of supramolecular approaches to nano-based features further equip the potential of designing novel approaches to overcome limitations seen by the conventional theranostic strategies, for curing even the lethal diseases and endowing personalized therapeutics with optimistic prognosis, endorsing their clinical translation. Among many potential nanocarriers for theranostics, lipid nanoparticles (LNPs) have shown various promising advances in theranostics and their formulation can be tailored for several applications. Despite the great advancement in cancer nanotheranostics, there are still many challenges that need to be highlighted to fill the literature gap. For this purpose, herein, we have presented a systematic overview on the subject and proposed LNPs as the potential material to manage cancer via non-invasive approaches by highlighting the use of supramolecular approaches to make them robust for cancer theranostics. We have concluded the review by entailing the future perspectives of lipid nanotheranostics towards clinical translation. Elsevier 2021-10-28 /pmc/articles/PMC8663983/ /pubmed/34909685 http://dx.doi.org/10.1016/j.crphar.2021.100067 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review Article
Bukhari, Syeda Zunaira
Zeth, Kornelius
Iftikhar, Maryam
Rehman, Mubashar
Usman Munir, Muhammad
Khan, Waheed S.
Ihsan, Ayesha
Supramolecular lipid nanoparticles as delivery carriers for non-invasive cancer theranostics
title Supramolecular lipid nanoparticles as delivery carriers for non-invasive cancer theranostics
title_full Supramolecular lipid nanoparticles as delivery carriers for non-invasive cancer theranostics
title_fullStr Supramolecular lipid nanoparticles as delivery carriers for non-invasive cancer theranostics
title_full_unstemmed Supramolecular lipid nanoparticles as delivery carriers for non-invasive cancer theranostics
title_short Supramolecular lipid nanoparticles as delivery carriers for non-invasive cancer theranostics
title_sort supramolecular lipid nanoparticles as delivery carriers for non-invasive cancer theranostics
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8663983/
https://www.ncbi.nlm.nih.gov/pubmed/34909685
http://dx.doi.org/10.1016/j.crphar.2021.100067
work_keys_str_mv AT bukharisyedazunaira supramolecularlipidnanoparticlesasdeliverycarriersfornoninvasivecancertheranostics
AT zethkornelius supramolecularlipidnanoparticlesasdeliverycarriersfornoninvasivecancertheranostics
AT iftikharmaryam supramolecularlipidnanoparticlesasdeliverycarriersfornoninvasivecancertheranostics
AT rehmanmubashar supramolecularlipidnanoparticlesasdeliverycarriersfornoninvasivecancertheranostics
AT usmanmunirmuhammad supramolecularlipidnanoparticlesasdeliverycarriersfornoninvasivecancertheranostics
AT khanwaheeds supramolecularlipidnanoparticlesasdeliverycarriersfornoninvasivecancertheranostics
AT ihsanayesha supramolecularlipidnanoparticlesasdeliverycarriersfornoninvasivecancertheranostics